A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
← catalyst calendarNCT06345339 · readout ≤ 407 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
2,800estimated
Sites
139
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-26 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypothyroidism
Interventions
- Drug: Armour Thyroid — also filed as AGN-282176
- Drug: Levothyroxine — also filed as Synthetic T4
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants who Achieve Thyroid-Stimulating Hormone (TSH) Response
measured Week 55
Number of Participants with Adverse Events (AEs)
measured Up to approximately 90 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed